QIAGEN Expands QIAstat-Dx with New Barcelona Innovation Hub
Portfolio | Nov 28, 2024 | Ysios Capital
QIAGEN has announced plans to relocate its QIAstat-Dx operations to a new site in Esplugues de Llobregat, Barcelona, as part of a multi-year investment to boost its infectious disease and precision medicine testing capabilities. The new facility, which is expected to open in 2026, will span 8,000 square meters and will serve as an innovation hub for the QIAstat-Dx system, supporting its development across the entire value chain. This strategic move aims to enhance diagnostic capabilities in diverse healthcare settings while also expanding the range of tests provided by the QIAstat-Dx system. With partnerships already in place with companies like Eli Lilly and AstraZeneca, QIAGEN is solidifying its commitment to precision medicine and rapid diagnostics, including tests for neurodegenerative, metabolic, and inflammatory diseases alongside traditional infectious disease testing.
Sectors
- Biotechnology & Pharmaceuticals
- Healthcare Technology
- Diagnostics & Research
Geography
- Spain – The article focuses on QIAGEN's expansion in Barcelona, where the new QIAstat-Dx innovation hub will be located.
- Netherlands – QIAGEN is a Netherlands-based company, highlighting its European roots and operational presence.
Industry
- Biotechnology & Pharmaceuticals – QIAGEN operates in this industry, focusing on molecular diagnostics and life sciences, providing tools to process and analyze DNA, RNA, and proteins.
- Healthcare Technology – The QIAstat-Dx system represents a significant advancement in healthcare technology, offering rapid diagnostics for infectious diseases and precision medicine.
- Diagnostics & Research – This industry is relevant due to QIAGEN's focus on developing diagnostic tools and research capabilities for disease identification and management.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| QIAGEN | Target Company | Company | A leading global provider of Sample to Insight solutions in molecular diagnostics and life sciences, expanding its operations in Barcelona. |
| Ysios Capital | Private Equity Firm | Company | A PE firm with interests in QIAGEN's strategic expansion and innovation in diagnostic technologies. |
| Eli Lilly | Strategic Partner | Company | Partnered with QIAGEN to support precision medicine applications in the QIAstat-Dx system. |
| AstraZeneca | Strategic Partner | Company | Collaborating with QIAGEN to advance precision medicine through the QIAstat-Dx system. |
| Barcelona Start-Up | Original Developer | Company | Originally developed the QIAstat-Dx technology before acquisition by QIAGEN in 2018. |